Sanofi (SNY )

Currency in USD Disclaimer
$53.66 -$1.27 (-2.31%)
Closed 10/21/2024
$53.51
$54.65
$42.63
$58.97

Company brief: SANOFI (SNY )


Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Corporation News

Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

October 21, 2024 at 4:35 pm ET

zacks.com -- SNY is negotiating with CD&R to sell a 50% stake in its consumer healthcare business, Opella....

French govt set to take stake in Sanofi unit after PE sale

October 21, 2024 at 7:06 am ET

proactiveinvestors.co.uk -- France is reportedly set to acquire a small stake in Sanofi SA's (ADR) (NYSE:SNY) consumer healthcare unit as the pharmaceutical company proceeds with a €16 billion deal to sell half of the busine...

Sanofi enters exclusive talks with CD&R for Opella sale

October 21, 2024 at 5:33 am ET

reuters.com -- Sanofi said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R)....

Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare

October 21, 2024 at 5:30 am ET

globenewswire.com -- Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant...

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

October 20, 2024 at 6:50 pm ET

reuters.com -- France will take a stake in Sanofi 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. priv...

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

October 17, 2024 at 1:05 pm ET

zacks.com -- Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers....

PAI Partners makes higher offer for Sanofi's Opella, says Le Monde

October 17, 2024 at 7:40 am ET

reuters.com -- French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayt...

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

October 17, 2024 at 1:30 am ET

globenewswire.com -- Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targete...

Income Statement